A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection
A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection
复制标题
DOI：
10.1212/wnl.51.6.1682
复制
发表时间：
1998-12-01
期刊：
影响因子：
9.9
通讯作者：
Cohen, B
中科院分区：
文献类型：
--
作者：
Kieburtz, K;Simpson, D;Cohen, B
背景：疼痛性感觉神经病变是HIV感染的常见并发症。基于先前的非对照观察，我们假设阿米替林或美西律会改善疼痛症状。方法：一项随机、双盲、为期10周的试验，145例患者平均分配到阿米替林、美西律或匹配的安慰剂组。主要结局指标是基线和最终访视之间疼痛强度的变化。结果如下：阿米替林组（0.31 +/- 0.31单位[平均值+/- SD]）和美西律组（0.23 +/- 0.41）的改善与安慰剂组（0.20 +/- 0.30）没有显著差异。两种干预措施通常耐受良好。结论：阿米替林和美西律都不能显著缓解HIV相关疼痛性感觉神经病变患者的疼痛。
Background: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. Method: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. Results: The improvement in amitriptyline group (0.31 +/- 0.31 units [mean +/- SD]) and mexiletine group (0.23 +/- 0.41) was not significantly different from placebo (0.20 +/- 0.30). Both interventions were generally well tolerated. Conclusions: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.